Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001995218-26-000006
Filing Date
2026-03-17
Accepted
2026-03-17 21:22:39
Documents
1
Period of Report
2026-03-13

Document Format Files

Seq Description Document Type Size
1 form4-03182026_010332.html 4  
1 form4-03182026_010332.xml 4 3619
  Complete submission text file 0001995218-26-000006.txt   5079
Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879
Lexeo Therapeutics, Inc. (Issuer) CIK: 0001907108 (see all company filings)

EIN.: 854012572 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, 6TH FLOOR NEW YORK NY 10010
Business Address
Townsend Richard Nolan (Reporting) CIK: 0001995218 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-41855 | Film No.: 26764608